📊 CVRX Key Takeaways
Is CVRx, Inc. (CVRX) a Good Investment?
CVRx is a pre-profitable medical device company with strong 87.2% gross margins indicating viable products, but is burning $12-13M annually in operating and free cash flows with no clear profitability timeline. While excellent liquidity ($72.3M cash) provides 5-6 years of runway and 10.4% revenue growth shows demand, the combination of negative operating leverage, 2.01x debt/equity ratio, and inability to cover interest from operations presents material downside risk for fundamental investors.
CVRx shows a strong gross margin profile and double-digit revenue growth, which suggests the core product economics are attractive. However, those positives are overwhelmed by extremely weak operating leverage, with operating and net losses near revenue scale, deeply negative free cash flow, and poor returns on capital. The balance sheet still has meaningful cash, but the current burn rate and leverage leave limited room for execution missteps unless revenue growth accelerates materially and losses narrow.
CVRx, Inc. Key Strengths (CVRX)
- Exceptional gross margin of 87.2% demonstrates strong underlying unit economics and product value
- Substantial cash position of $72.3M relative to company size provides operational runway
- Revenue growth of 10.4% YoY with stabilizing losses (EPS improved 23% YoY) suggests operational efficiency gains
- High gross margin of 85.3% indicates favorable unit economics and pricing power
- Revenue grew 10.4% year over year, showing ongoing commercial adoption
- Strong liquidity ratios and $75.71M of cash provide near-term operating flexibility
CVRX Stock Risks: CVRx, Inc. Investment Risks
- Negative operating cash flow (-$12.2M) and free cash flow (-$12.3M) indicate ongoing cash burn from core operations
- High leverage (2.01x debt/equity) combined with negative interest coverage (-12.7x) creates refinancing risk
- Pre-profitable status with $14.8M revenue generating -$12.2M operating loss indicates significant scaling risk before profitability
- Operating margin of -90.5% and net margin of -94.1% show the business remains far from self-sustaining
- Free cash flow of -$40.75M versus $75.71M cash implies a short runway if burn does not improve
- Debt/equity of 1.26x and negative interest coverage indicate meaningful balance-sheet and financing risk
Key Metrics to Watch
- Path to operating profitability and operating margin trend trajectory
- Quarterly cash burn rate relative to cash reserves and runway estimate
- Revenue growth acceleration and gross margin sustainability as scale increases
- Revenue growth relative to operating expense growth
- Quarterly free cash flow burn and ending cash balance
CVRx, Inc. (CVRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.20x current ratio provides a solid financial cushion.
CVRX Profit Margin, ROE & Profitability Analysis
CVRX vs Healthcare Sector: How CVRx, Inc. Compares
How CVRx, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CVRx, Inc. Stock Overvalued? CVRX Valuation Analysis 2026
Based on fundamental analysis, CVRx, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CVRx, Inc. Balance Sheet: CVRX Debt, Cash & Liquidity
CVRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CVRx, Inc.'s revenue has grown significantly by 335% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.65 indicates the company is currently unprofitable.
CVRX Revenue Growth, EPS Growth & YoY Performance
CVRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $12.3M | -$13.1M | $-0.50 |
| Q3 2025 | $13.4M | -$12.9M | $-0.49 |
| Q2 2025 | $11.8M | -$14.0M | $-0.57 |
| Q1 2025 | $10.8M | -$13.8M | $-0.53 |
| Q3 2024 | $10.5M | -$9.0M | $-0.43 |
| Q2 2024 | $9.5M | -$11.7M | $-0.56 |
| Q1 2024 | $8.0M | -$11.4M | $-0.55 |
| Q3 2023 | $6.2M | -$9.0M | $-0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CVRx, Inc. Dividends, Buybacks & Capital Allocation
CVRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CVRx, Inc. (CIK: 0001235912)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CVRX
What is the AI rating for CVRX?
CVRx, Inc. (CVRX) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CVRX's key strengths?
Claude: Exceptional gross margin of 87.2% demonstrates strong underlying unit economics and product value. Substantial cash position of $72.3M relative to company size provides operational runway. ChatGPT: High gross margin of 85.3% indicates favorable unit economics and pricing power. Revenue grew 10.4% year over year, showing ongoing commercial adoption.
What are the risks of investing in CVRX?
Claude: Negative operating cash flow (-$12.2M) and free cash flow (-$12.3M) indicate ongoing cash burn from core operations. High leverage (2.01x debt/equity) combined with negative interest coverage (-12.7x) creates refinancing risk. ChatGPT: Operating margin of -90.5% and net margin of -94.1% show the business remains far from self-sustaining. Free cash flow of -$40.75M versus $75.71M cash implies a short runway if burn does not improve.
What is CVRX's revenue and growth?
CVRx, Inc. reported revenue of $14.8M.
Does CVRX pay dividends?
CVRx, Inc. does not currently pay dividends.
Where can I find CVRX SEC filings?
Official SEC filings for CVRx, Inc. (CIK: 0001235912) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CVRX's EPS?
CVRx, Inc. has a diluted EPS of $-0.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CVRX's fundamental grade?
Based on our AI fundamental analysis in June 2026, CVRx, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CVRX stock overvalued or undervalued?
Valuation metrics for CVRX: ROE of -45.1% (sector avg: 15%), net margin of -88.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CVRX's AI grade for 2026?
Our dual AI analysis gives CVRx, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CVRX's free cash flow?
CVRx, Inc.'s operating cash flow is $-12.2M, with capital expenditures of $122.0K. FCF margin is -83.2%.
How does CVRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -88.8% (avg: 12%), ROE -45.1% (avg: 15%), current ratio 10.20 (avg: 2).
Is CVRx, Inc. carrying too much debt?
CVRX has a debt-to-equity ratio of 2.01x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 10.20 suggests adequate short-term liquidity.